Can we predict immunotherapy success by forecasting severe radiation-induced lymphopenia (RIL)? A pretreatment NSCLC nomogram shows only low RIL-risk patients benefit from adjuvant durvalumab, potentially enabling personalized RIL mitigation and optimized immunotherapy. Read it here in the RedJournal.

Severe radiation-induced lymphopenia (RIL) during concurrent chemoradiotherapy (CCRT) for NSCLC has been associated with poorer outcomes and reduced immunotherapy efficacy. Because RIL often develops late during CCRT, identifying patients at risk before treatment may be clinically relevant. This study aimed to develop and validate a nomogram based on pretreatment predictors for severe RIL, and secondarily to explore associations between predicted RIL risk and adjuvant durvalumab-associated survival.